journal article·2022-03Open access

Multifunctional Biomimetic Nanovaccines Based on Photothermal and Weak‐Immunostimulatory Nanoparticulate Cores for the Immunotherapy of Solid Tumors

Jiachen Li, Di Huang, Ruoyu Cheng, Patrícia Figueiredo, Flavia Fontana, Alexandra Correia, Shiqi Wang, Zehua Liu, Marianna Kemell, Giulia Torrieri, Ermei M. Mäkilä, Jarno J. Salonen, Jouni Hirvonen, Yan Gao, Jialiang Li, Zhenyang Luo, Hélder A. Santos, Bing Xia

Advanced Materials· Volume 34· Issue 9

Abstract

Abstract An alternative strategy of choosing photothermal and weak‐immunostimulatory porous silicon@Au nanocomposites as particulate cores to prepare a biomimetic nanovaccine is reported to improve its biosafety and immunotherapeutic efficacy for solid tumors. A quantitative analysis method is used to calculate the loading amount of cancer cell membranes onto porous silicon@Au nanocomposites. Assisted with foreign‐body responses, these exogenous nanoparticulate cores with weak immunostimulatory effect can still efficiently deliver cancer cell membranes into dendritic cells to activate them and the downstream antitumor immunity, resulting in no occurrence of solid tumors and the survival of all immunized mice during 55 day observation. In addition, this nanovaccine, as a photothermal therapeutic agent, synergized with additional immunotherapies can significantly inhibit the growth and metastasis of established solid tumors, via the initiation of the antitumor immune responses in the body and the reversion of their immunosuppressive microenvironments. Considering the versatile surface engineering of porous silicon nanoparticles, the strategy developed here is beneficial to construct multifunctional nanovaccines with better biosafety and more diagnosis or therapeutic modalities against the occurrence, recurrence, or metastasis of solid tumors in future clinical practice.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Science Nanjing Forestry University Nanjing 210037 China

Drug Research Program Division of Pharmaceutical Chemistry and Technology University of Helsinki Helsinki FI‐00014 Finland

Department of Biomedical Engineering and W.J. Kolff Institute for Biomedical Engineering and Materials Science University of Groningen/University Medical Center Groningen Ant. Deusinglaan 1 Groningen 9713 AV The Netherlands

Department of Chemistry University of Helsinki Helsinki FI‐00014 Finland

Laboratory of Industrial Physics Department of Physics and Astronomy University of Turku Turku FI‐20014 Finland

Funding

Sigrid Juséliuksen Säätiö · Academy of Finland · National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province · Terveyden Tutkimuksen Toimikunta

References (50)

Show source-provided references
1. 10.4049/jimmunol.090253910.4049/jimmunol.0902539 ↗
2. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
3. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
4. 10.3390/vaccines303066210.3390/vaccines3030662 ↗
5. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
6. 10.1016/j.addr.2020.07.02310.1016/j.addr.2020.07.023 ↗
7. 10.1038/s41563-020-0793-610.1038/s41563-020-0793-6 ↗
8. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
9. 10.1038/s41565-020-00782-310.1038/s41565-020-00782-3 ↗
10. 10.7150/jca.1.23010.7150/jca.1.230 ↗
11. 10.1002/adbi.20180021910.1002/adbi.201800219 ↗
12. 10.1002/adma.20170675910.1002/adma.201706759 ↗
13. 10.1093/nsr/nwz03710.1093/nsr/nwz037 ↗
14. 10.1038/s41563-018-0028-210.1038/s41563-018-0028-2 ↗
15. 10.1126/science.aar711210.1126/science.aar7112 ↗
16. 10.1002/adma.20190125510.1002/adma.201901255 ↗
17. 10.1016/j.jconrel.2017.08.00910.1016/j.jconrel.2017.08.009 ↗
18. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
19. 10.1038/nature1297810.1038/nature12978 ↗
20. Bodey B. · Anticancer Res. · 2000 · 20 · 2665
21. 10.1038/nrc.2016.1610.1038/nrc.2016.16 ↗
22. 10.1007/s13346-021-00923-810.1007/s13346-021-00923-8 ↗
23. 10.1038/ncomms1319310.1038/ncomms13193 ↗
24. 10.1002/adma.20180593610.1002/adma.201805936 ↗
25. 10.1002/adma.20200478810.1002/adma.202004788 ↗
26. 10.1002/adfm.20180468810.1002/adfm.201804688 ↗
27. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
28. 10.1016/j.biomaterials.2014.07.05010.1016/j.biomaterials.2014.07.050 ↗
29. 10.1002/adma.20160323910.1002/adma.201603239 ↗
30. 10.1021/acsnano.8b0961310.1021/acsnano.8b09613 ↗
31. 10.1002/adhm.20200052910.1002/adhm.202000529 ↗
32. 10.1021/acsbiomaterials.8b0153310.1021/acsbiomaterials.8b01533 ↗
33. 10.1021/nl204203t10.1021/nl204203t ↗
34. 10.1021/acsami.6b0300810.1021/acsami.6b03008 ↗
35. 10.1021/acsami.7b1327810.1021/acsami.7b13278 ↗
36. 10.1016/j.jconrel.2021.07.01210.1016/j.jconrel.2021.07.012 ↗
37. 10.1016/S1471-4906(02)02195-610.1016/S1471-4906(02)02195-6 ↗
38. 10.1016/j.biomaterials.2014.11.04510.1016/j.biomaterials.2014.11.045 ↗
39. 10.1002/(SICI)1521-4141(199908)29:08<2367::AID-IMMU2367>3.0.CO;2-310.1002/(SICI)1521-4141(199908)29:08<2367::AID-IMMU2367>3.0.CO;2-3 ↗
40. 10.1016/j.biomaterials.2018.08.01610.1016/j.biomaterials.2018.08.016 ↗
41. 10.1126/sciadv.aaw687010.1126/sciadv.aaw6870 ↗
42. 10.1016/j.addr.2019.08.01010.1016/j.addr.2019.08.010 ↗
43. 10.2217/nnm-2016-019510.2217/nnm-2016-0195 ↗
44. 10.1002/adhm.20110000510.1002/adhm.201100005 ↗
45. 10.1146/annurev.immunol.22.012703.10470210.1146/annurev.immunol.22.012703.104702 ↗
46. 10.1038/nri386210.1038/nri3862 ↗
47. 10.1038/s41565-020-00822-y10.1038/s41565-020-00822-y ↗
48. 10.1038/nri339910.1038/nri3399 ↗
49. 10.1002/adma.20200848110.1002/adma.202008481 ↗
50. 10.1021/acsnano.1c0561810.1021/acsnano.1c05618 ↗